UCLA, UCSF gain FDA approval for prostate cancer imaging technique
The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a...Read More
The Prostate Cancer Foundation and Robert F. Smith Announce New Effort to Address Health Disparities for African American Men
LOS ANGELES, Calif., July 21, 2020 – The Prostate Cancer Foundation (PCF) and Robert F. Smith, founder, chairman and CEO of Vista Equity Partners, announce a new effort to reduce...Read More
Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients...Read More
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy
Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical...Read More
FDA approves enzalutamide for metastatic castration-sensitive prostate cancer
December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Enzalutamide has...Read More
FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer
July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Non-metastatic CRPC is a clinical...Read More
Prostate Cancer Foundation’s Statement on Late-Breaking ASCO Presentation Regarding Racial Differences in Prostate Cancer and Call for Greater Diversity in Clinical Trial Participation
JUNE 1, 2018 - Each year three million men in the U.S. battle prostate cancer and on average one in nine men will be diagnosed in their lifetime. However, there...Read More
Prostate Cancer Foundation Statement on U.S. Preventive Services Task Force Updated Prostate Screening Guidelines
Yesterday, the USPSTF updated its 2012 position on prostate cancer screening recommending that clinicians should selectively offer or provide periodic prostate-specific antigen (PSA)–based screening for prostate cancer for men between...Read More
Clinical trial finds strong promise for new treatment that targets radiation directly to prostate cancer
May 8, 2018 A study published today in Lancet Oncology reported highly promising results from a phase 2 clinical trial testing a new treatment, 177Lu-PSMA-617, which targets radiation directly to prostate...Read More
New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes
Thanks in large part to the kinds of genetic and precision medicine that the Prostate Cancer Foundation has been funding, the National Comprehensive Cancer Network (NCCN) has issued updated prostate...Read More
- 1
- 2